Bli medlem
Bli medlem

Du är här

2016-05-17

Novartis International AG: Novartis focuses Pharmaceuticals Division by creating two business units, Novartis Pharmaceuticals and Novartis Oncology; appoints le

Novartis International AG / Novartis focuses Pharmaceuticals Division by
creating two business units,Novartis Pharmaceuticals and Novartis Oncology;
appoints leaders to the Executive Committee of Novartis. Processed and
transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely
responsible for the content of this announcement.
* Paul Hudson appointed CEO, Novartis Pharmaceuticals, and Bruno Strigini
appointed CEO, Novartis Oncology; David Epstein to leave Novartis
* Paul Hudson and Bruno Strigini appointed to the Executive Committee of
Novartis
* Novartis Pharmaceuticals and Novartis Oncology will form the Innovative
Medicines Division at Novartis

Basel, May 17, 2016 -
Novartis announced today changes to focus its Pharmaceuticals Division by
creating two business units reporting to the CEO: Novartis Pharmaceuticals
and Novartis Oncology. These business units will form the Innovative
Medicines Division at Novartis. The leader of each business will join the
Executive Committee of Novartis (ECN) effective July 1, 2016. Paul Hudson
will be appointed CEO, Novartis Pharmaceuticals and Bruno Strigini will
become CEO, Novartis Oncology. Both will report directly to Joseph Jimenez,
CEO of Novartis. With these changes, David Epstein, currently Division Head
and CEO, Novartis Pharmaceuticals, has decided to leave Novartis.

The new structure reflects the importance of oncology to Novartis following
the successful integration of the oncology assets acquired from GSK. Novartis
expects this change to help drive our growth and innovation strategy, with an
increased focus and improved execution for both the Novartis Oncology and
Novartis Pharmaceuticals business units.

Paul Hudson
, currently Executive Vice President, North America and member of the
Executive Committee, AstraZeneca, will join Novartis and lead Novartis
Pharmaceuticals. Prior to his role in North America, Paul Hudson served as
the leader of AstraZeneca's Japanese business. Novartis Pharmaceuticals will
include the franchises Neuroscience, Ophthalmology, Immunology and
Dermatology, Respiratory, Cardio-Metabolic and Established Medicines. Mr.
Hudson has broad pharmaceutical industry experience and in particular in
cardiovascular and immunology, which complement Novartis' major product
launches. He will be based at the global headquarters of the Innovative
Medicines Division and the Novartis Pharmaceuticals business unit, which will
be in Basel, Switzerland.

Bruno Strigini
, currently Head of Novartis Oncology, will lead the Novartis Oncology
business unit, comprised of the franchises Oncology and Cell and Gene
Therapies. Mr. Strigini joined Novartis in 2014 from Merck&Co. to lead the
oncology business and was instrumental in the successful integration of the
oncology assets acquired from GSK. He will be based at the global
headquarters of the Innovative Medicines Division and the Novartis Oncology
business unit which will be in Basel, Switzerland.

David Epstein,
currently Division Head and CEO of Novartis Pharmaceuticals, has decided to
leave Novartis and explore new challenges from the US. "We would like to
thank David for his substantial contribution to the development and growth of
Novartis and its people over many years. He built our leading Oncology
business and over the last six years has steered our Pharmaceuticals Division
through a period of excellence in innovation, execution and improved
financial results. Over the course of his career he and his teams have been
responsible for leading the development and commercialization of an industry
leading number of new medicines including groundbreaking therapies such as
Glivec®, Gilenya®, Cosentyx® and Entresto(TM). I want to express my personal
appreciation for all David has done for Novartis and patients and wish him
continued success," said Joe Jimenez, CEO of Novartis.

From July 1, 2016 Novartis will continue to have three focused,
customer-facing divisions: Innovative Medicines (formerly the Novartis
Pharmaceuticals division), which will include the Novartis Pharmaceuticals
and Novartis Oncology business units; Sandoz, the generics and biosimilar
division, which includes the Retail Generics, Anti-Infectives and
Biopharmaceuticals franchises; and Alcon, the eye care devices division,
which includes the Surgical and Vision Care franchises. The divisions will be
supported by Novartis Institutes for BioMedical Research, Global Drug
Development and Novartis Operations, which includes Technical Operations and
Novartis Business Services.

Disclaimer

The foregoing release contains forward-looking statements that can be
identified by words such as "to leave," "will," "to focus," "expect," or
similar terms, or by express or implied discussions regarding the potential
impact of the creation of the Pharmaceuticals and Oncology business units
within our Innovative Medicines Division, or of the announced changes in
leadership. You should not place undue reliance on these statements. Such
forward-looking statements are based on the current beliefs and expectations
of management regarding future events, and are subject to significant known
and unknown risks and uncertainties. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those set forth in the
forward-looking statements. There can be no guarantee that the creation of
the Pharmaceuticals and Oncology business units within our Innovative
Medicines Division, or the announced changes in leadership will have any
particular impact on Novartis. In particular, management's expectations could
be affected by, among other things, the uncertainties inherent in research
and development, including unexpected research or clinical trial results and
additional analysis of existing data; unexpected regulatory actions or delays
or government regulation generally; the company's ability to obtain or
maintain proprietary intellectual property protection; general economic and
industry conditions; global trends toward health care cost containment,
including ongoing pricing pressures; uncertainties regarding actual or
potential legal proceedings; unexpected safety, quality or manufacturing
issues; general economic and industry conditions, including uncertainties
regarding future global exchange rates; uncertainties regarding potential
significant breaches of data security or disruptions of our information
technology systems; and other risks and factors referred to in Novartis AG's
current Form 20-F on file with the US Securities and Exchange Commission.
Novartis is providing the information in this press release as of this date
and does not undertake any obligation to update any forward-looking
statements contained in this press release as a result of new information,
future events or otherwise.

About Novartis

Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland,
Novartis offers a diversified portfolio to best meet these needs: innovative
medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the
only global company with leading positions in these areas. In 2015, the Group
achieved net sales of USD 49.4 billion, while R&D throughout the Group
amounted to approximately USD 8.9 billion (USD 8.7 billion excluding
impairment and amortization charges). Novartis Group companies employ
approximately 118,000 full-time-equivalent associates. Novartis products are
available in more than 180 countries around the world. For more information,
please visithttp://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis
athttp://twitter.com/novartis.

For Novartis multimedia content, please
visitwww.novartis.com/news/media-library. For questions about the site or
required registration, please contact:media.relations@novartis.com

# # #

Novartis Media Relations

-------------------------------------------------------------------
| Central media line : |
|+41 61 324 2200 |
| Paul Barrett Eric Althoff |
| |
|Novartis External Communications Novartis Global Media Relations |
|+41 61 324 5224 (direct) +1 212 830 2408 (direct) |
|+41 79 797 8137 (mobile) +1 646 438 4335 (mobile) |
|paul.barrett@novartis.com eric.althoff@novartis.com |
-------------------------------------------------------------------
e-mail:media.relations@novartis.com

Novartis Investor Relations

----------------------------------------------------------------------------------
| Central phone: +41 61 324 7944 |
| Samir Shah +41 61 324 7944 North America: |
| Pierre-Michel Bringer +41 61 324 1065 Richard Pulik +1 212 830 2448 |
| Thomas Hungerbuehler +41 61 324 8425 Sloan Pavsner +1 212 830 2417 |
| Isabella Zinck +41 61 324 7188 |
| |
| e-mail:investor.relations@novartis.com e-mail:investor.relations@novartis.com |
----------------------------------------------------------------------------------

Media release (PDF)
http://hugin.info/134323/R/2013270/746063.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novartis International AG via Globenewswire

HUG#2013270

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.